Management of Atopy with Dupilumab and Omalizumab in CADINS Disease

Natalie M. Diaz-Cabrera, Bradly M. Bauman, Mildred A. Iro, Gina Dabbah-Krancher, Vered Molho-Pessach, Abraham Zlotogorski, Oded Shamriz, Yael Dinur-Schejter, Tatyana Dubnikov Sharon, Polina Stepensky, Yuval Tal, Eli M. Eisenstein, Leonora Pietzsch, Catharina Schuetz, Damien Abreu, Carrie C. Coughlin, Megan A. Cooper, Joshua D. Milner, Anthony Williams, Gil Armoni-WeissAndrew L. Snow, Jennifer W. Leiding

Research output: Contribution to journalArticlepeer-review


The caspase activation and recruitment domain 11 (CARD11) gene encodes a scaffold protein required for lymphocyte antigen receptor signaling. Dominant-negative, loss-of-function (LOF) pathogenic variants in CARD11 result in CARD11-associated atopy with dominant interference of NF-κB signaling (CADINS) disease. Patients with CADINS suffer with severe atopic manifestations including atopic dermatitis, food allergy, and chronic spontaneous urticaria in addition to recurrent infections and autoimmunity. We assessed the response of dupilumab in five patients and omalizumab in one patient with CADINS for the treatment of severe atopic symptoms. CARD11 mutations were validated for pathogenicity using a T cell transfection assay to assess the impact on activation-induced signaling to NF-κB. Three children and three adults with dominant-negative CARD11 LOF mutations were included. All developed atopic disease in infancy or early childhood. In five patients, atopic dermatitis was severe and recalcitrant to standard topical and systemic medications; one adult suffered from chronic spontaneous urticaria. Subcutaneous dupilumab was initiated to treat atopic dermatitis and omalizumab to treat chronic spontaneous urticaria. All six patients had rapid and sustained improvement in atopic symptoms with no complications during the follow-up period. Previous medications used to treat atopy were able to be decreased or discontinued. In conclusion, treatment with dupilumab and omalizumab for severe, refractory atopic disease in patients with CADINS appears to be effective and well tolerated in patients with CADINS with severe atopy.

Original languageEnglish
Article number48
JournalJournal of Clinical Immunology
Issue number2
StatePublished - Feb 2024


  • CARD11
  • atopic dermatitis
  • dupilumab
  • eczema
  • omalizumab
  • urticaria


Dive into the research topics of 'Management of Atopy with Dupilumab and Omalizumab in CADINS Disease'. Together they form a unique fingerprint.

Cite this